Literature DB >> 26776245

Teledermoscopy in High-risk Melanoma Patients: A Comparative Study of Face-to-face and Teledermatology Visits.

Edith Arzberger1, Clara Curiel-Lewandrowski, Andreas Blum, Dmitry Chubisov, Amanda Oakley, Marius Rademaker, Hans Soyer, Rainer Hofmann-Wellenhof.   

Abstract

Teledermoscopy is considered a reliable tool for the evaluation of pigmented skin lesions. We compared the management decision in face-to-face visits vs. teledermatology in a high-risk melanoma cohort using total-body photography, macroscopic and dermoscopic images of single lesions. Patients were assessed both face-to face and by 4 remote teledermatologists. Lesions identified as suspicious for skin cancer by face-to-face evaluation underwent surgical excision. The teledermatologists recommended "self-monitoring", "short-term monitoring", or "excision". A 4-year monitoring was completed in a cohort of participating subjects. The general agreement, calculated by prevalence and bias-adjusted κ (PABAK), showed almost perfect agreement (PABAK 0.9-0.982). A total of 23 lesions were excised; all teledermatologists identified the 9 melanomas. The greatest discrepancy was detected in "short-term monitoring". During 4-year monitoring one melanoma was excised that had been considered benign. In conclusion, melanoma identification by experts in pigmented lesions appears to be equivalent between face-to-face and teledermatological consultation.

Entities:  

Mesh:

Year:  2016        PMID: 26776245     DOI: 10.2340/00015555-2344

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  8 in total

1.  Teledermatology for diagnosing skin cancer in adults.

Authors:  Naomi Chuchu; Jacqueline Dinnes; Yemisi Takwoingi; Rubeta N Matin; Susan E Bayliss; Clare Davenport; Jacqueline F Moreau; Oliver Bassett; Kathie Godfrey; Colette O'Sullivan; Fiona M Walter; Richard Motley; Jonathan J Deeks; Hywel C Williams
Journal:  Cochrane Database Syst Rev       Date:  2018-12-04

2.  Improving Diagnostic Accuracy of Dermoscopically Equivocal Pink Cutaneous Lesions with Reflectance Confocal Microscopy in Telemedicine Settings: Double Reader Concordance Evaluation of 316 Cases.

Authors:  J Łudzik; A M Witkowski; I Roterman-Konieczna; S Bassoli; F Farnetani; G Pellacani
Journal:  PLoS One       Date:  2016-09-08       Impact factor: 3.240

3.  Improving diagnostic sensitivity of combined dermoscopy and reflectance confocal microscopy imaging through double reader concordance evaluation in telemedicine settings: A retrospective study of 1000 equivocal cases.

Authors:  A M Witkowski; J Łudzik; F Arginelli; S Bassoli; E Benati; A Casari; N De Carvalho; B De Pace; F Farnetani; A Losi; M Manfredini; C Reggiani; J Malvehy; G Pellacani
Journal:  PLoS One       Date:  2017-11-09       Impact factor: 3.240

4.  Application of Teledermoscopy in the Diagnosis of Pigmented Lesions.

Authors:  C B Barcaui; P M O Lima
Journal:  Int J Telemed Appl       Date:  2018-10-10

5.  Recent trends in teledermatology and teledermoscopy.

Authors:  Katie J Lee; Anna Finnane; H Peter Soyer
Journal:  Dermatol Pract Concept       Date:  2018-07-31

6.  Teledermoscopy as a community based diagnostic test in the era of COVID-19?

Authors:  A Lowe; A Atwan; C Mills
Journal:  Clin Exp Dermatol       Date:  2020-08-26       Impact factor: 4.481

Review 7.  Teledermatology: idea, benefits and risks of modern age - a systematic review based on melanoma.

Authors:  Paulina Pala; Beata S Bergler-Czop; Jakub M Gwiżdż
Journal:  Postepy Dermatol Alergol       Date:  2020-05-05       Impact factor: 1.837

8.  Emergency Use and Efficacy of an Asynchronous Teledermatology System as a Novel Tool for Early Diagnosis of Skin Cancer during the First Wave of COVID-19 Pandemic.

Authors:  Antal Jobbágy; Norbert Kiss; Fanni Adél Meznerics; Klára Farkas; Dóra Plázár; Szabolcs Bozsányi; Luca Fésűs; Áron Bartha; Endre Szabó; Kende Lőrincz; Miklós Sárdy; Norbert Miklós Wikonkál; Péter Szoldán; András Bánvölgyi
Journal:  Int J Environ Res Public Health       Date:  2022-02-25       Impact factor: 4.614

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.